The earnings call highlighted the successful internalization of the commercial team, pipeline expansion, and strong financial management. However, these positives were offset by a decline in Q1 revenue, regulatory hurdles with EUA expansion, and challenges in healthcare provider adoption. The company expressed confidence in its strategic direction and financial discipline but faces significant challenges in execution and regulatory approval.

Company Guidance -

Q1 2025

During Invivyd’s First Quarter 2025 Earnings Conference Call, the company provided guidance that emphasized the transition to an internal commercial organization, aiming for near-term breakeven with ongoing revenue growth and operating expense management. The management highlighted a strategic focus on broader adoption of PEMGARDA, with promising leading indicators for commercial success. Invivyd secured additional non-dilutive capital contingent on meeting certain conditions and milestones and is expanding its pipeline beyond COVID-19, including discovery programs in new viral targets and diseases such as RSV and measles. The company's strategy includes disciplined financial management, targeting profitability by mid-2025, and leveraging its scientific platform to create shareholder value efficiently. The guidance reflects a commitment to developing high-value medicines rapidly, despite the challenging biotech financing environment.

Internalization of Commercial Organization

The company successfully transitioned to an internal commercial team, which is expected to drive broader adoption of PEMGARDA, with promising early indicators for near-term breakeven and continued revenue growth.

Pipeline Expansion and Discovery Programs

The company expanded its pipeline to include discovery programs targeting new viral diseases such as RSV and measles, aiming to create best-in-class medicines beyond COVID-19.

Strong Financial Position and Cost Management

The company reported $11.3 million in net product revenue for Q1 2025 and a reduction in operating expenses by 15% quarter-over-quarter, with a strong cash position of $48 million and potential access to $30 million in non-dilutive funding.

Inclusion in Clinical Guidelines

PEMGARDA has been included in the NCCN Guidelines for B-cell lymphomas, indicating recognition from medical guidelines for its usage.

Invivyd (IVVD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IVVD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 19, 2025	2025 (Q2)	-0.02 / -	-0.4	―	―	―
May 15, 2025	2025 (Q1)	-0.03 / -0.14	-0.38	63.16% (+0.24)
Mar 20, 2025	2024 (Q4)	-0.20 / -0.15	-0.67	77.61% (+0.52)	―	―
Nov 14, 2024	2024 (Q3)	-0.34 / -0.51	-0.36	-41.67% (-0.15)
Aug 14, 2024	2024 (Q2)	-0.37 / -0.40	-0.46	13.04% (+0.06)
May 09, 2024	2024 (Q1)	-0.47 / -0.38	-0.32	-18.75% (-0.06)
Mar 28, 2024	2023 (Q4)	-0.43 / -0.67	-0.41	-63.41% (-0.26)	―	―
Nov 09, 2023	2023 (Q3)	-0.51 / -0.36	-0.42	14.29% (+0.06)
Aug 10, 2023	2023 (Q2)	-0.37 / -0.46	-0.47	2.13% (<+0.01)	―
May 11, 2023	2023 (Q1)	-0.34 / -0.32	-0.93	65.59% (+0.61)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

IVVD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 15, 2025	$0.84	$0.70	-16.67%
Mar 20, 2025	$0.72	$0.74	+2.78%
Nov 14, 2024	$0.89	$0.79	-11.24%
Aug 14, 2024	$1.06	$0.98	-7.55%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Invivyd (IVVD) report earnings?

Invivyd (IVVD) is schdueled to report earning on Aug 19, 2025, Before Open (Confirmed).

What is Invivyd (IVVD) earnings time?

Invivyd (IVVD) earnings time is at Aug 19, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is IVVD EPS forecast?

IVVD EPS forecast for the fiscal quarter 2025 (Q2) is -0.02.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing